BRANCHBURG, N.J., Jan. 12 /PRNewswire-FirstCall/ -- LifeCell Corporation , today announced plans to release preliminary fourth quarter 2005 revenues and 2006 financial guidance on Tuesday, January 24, 2006 at 8:00 a.m. Eastern. Paul Thomas, President and Chief Executive Officer, will host a conference call at 10:00 a.m. Eastern, to discuss the Company’s fourth quarter 2005 revenues and expected financial performance for 2006.
The dial-in number for the live call is (800) 289-0493/domestic or (913) 981-5510/international. A simultaneous webcast of the call will be available via LifeCell’s website at http://www.lifecell.com Corporate Information -- Investor Relations. The call will be archived on the Company’s website for at least 90 days.
A recording of the live-call will be available through January 31, 2006. The dial-in number to listen to the recording is (888) 203-1112 or (719) 457-0820. The replay access code is 5223491.
About LifeCell
LifeCell develops and markets products made from human tissue for use in reconstructive, orthopedic and urogynecologic surgical procedures. The Company’s patented technology produces a unique regenerative human tissue matrix -- a complex three-dimensional structure that contains an array of proteins, growth factor binding sites and vascular channels -- that provides a complete template for the regeneration of normal human tissue. LifeCell’s current products include: AlloDerm(R) for plastic reconstructive, general surgical, burn and periodontal procedures; Cymetra(R), a particulate form of AlloDerm suitable for injection; GraftJacket(R) and GraftJacket(R) Xpress for orthopedic applications and lower extremity wounds; AlloCraft(TM)DBM, for bone grafting procedures; and Repliform(R) for urogynecologic surgical procedures. LifeCell markets AlloDerm for plastic reconstructive, general surgical and burn applications through its direct sales organization. The Company’s strategic sales and marketing partners include: Wright Medical Group, Inc. for GraftJacket, Stryker Corporation for AlloCraftDBM, Boston Scientific for Repliform, and BioHorizons for periodontal applications of AlloDerm. The Company’s research and development initiatives include programs focused on extending the use of its regenerative tissue matrix products into new surgical applications, leveraging its core technology to other tissues, including non-human tissues and expanding its product line in the rapidly growing biologic market. LifeCell maintains a website at http://www.lifecell.com.
LifeCell Corporation
CONTACT: Steven T. Sobieski, Chief Financial Officer of LifeCellCorporation, +1-908-947-1106, ssobieski@lifecell.com; or Kevin McGrath ofCameron Associates, +1-212-245-8800, kevin@cameronassoc.com, for LifeCellCorporation
Web site: http://www.lifecell.com/
